Teduglutide (Revestive) EU approval (2012)
The European Commission approved teduglutide, the first GLP-2 analog, for short bowel syndrome. It was a breakthrough, the first drug shown to help patients reduce their dependence on IV nutrition, but it required daily subcutaneous injections.
Teduglutide became the standard add-on therapy for SBS across Europe.
It validated the GLP-2 mechanism and opened the field for longer-acting analogs.
Zeydovio uses the same mechanism with a longer half-life, given twice weekly instead of daily, which is the improvement that could broaden who benefits.
